In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
ESMO BREAST CANCER Virtual Meeting 2020 23-24. May 2020
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
Hinweise um die Patienten während der COVID-19-Pandemie in der klinischen Studie bestmöglich und protokollkonform zu behandeln.
Highlights und Interviews vom GBG Jahrestreffen
We are pleased to inform you that the surgical results of the randomized BrighTNess trial have been published in JAMA Surgery.
DIe GBG beobachtet die Situation bzgl Coronavirus/Covid-19 und trifft entsprechende Vorbereitungen.
We are delighted to inform you that the long-term follow-up results of the randomized IBIS-II trial have been published in Lancet.
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
ESMO Breast Cancer 2020 will take place on 7-9 May 2020 in Berlin, Germany.
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
MammaMia! Patientenkongress Gynäkologische Krebserkrankungen am 2. Februar in Frankfurt.
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress